Merck, 681679-10MG, Iron Chelator IV, 21H7

General description
A cell-permeable salicylaldehyde-acylhydrazone iron chelator that is 20-times more efficient than DFO/desferrioxamine (Cat. No. 252750) in depleting intracellular iron in colon cancer SW480 cells. Iron chelators exert their biological activities by affecting iron-regulated enzymes and singaling events, including HIF1α transcription activation (Effective [21H7] = 10 µM in SW480 and DLD-1 cells) due to inhibition of PHD- (prolyl hydroxylase) mediated HIF1α degradation, as well as stalling and enhancing, respectively, Ferritin and TfRI (Transferrin Receptor I) mRNA translation (Effective [21H7] = 10 µM in SW480 cells) due to iron depletion-induced IRP (Iron Regulatory Protein) IREs (Iron Response Elements) binding. Iron depletion is also reported to inhibit the growths of colorectal adenocarcinoma cultures, DLD-1 (IC₅₀ = 0.6 and 2.9 µM, respectively, by 21H7 and DFO) and SW480 (IC₅₀ = 1.0 and 3.8 µM, respectively, by 21H7 and DFO), as a result of Wnt signaling pathway blockage (Effective conc. = 5 µM 21H7 or 100 µM DFO).
Preparation Note
Slight warming (45°C) is required for complete solubilization.
Other Notes
Song, S., et al. 2011. Cancer Res.71, 7628.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)